Need professional-grade analysis? Visit stockanalysis.com
$70.39M
N/A
N/A
N/A
Gain Therapeutics Inc (GANX) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $1.89, down 7.35% from the previous close.
Over the past year, GANX has traded between a low of $1.44 and a high of $4.18. The stock has lost 1.0% over this period. It is currently 54.8% below its 52-week high.
Gain Therapeutics Inc has a market capitalization of $70.39M.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Side-by-side comparison against top Healthcare peers.